Current Edition


Vertex adds to Boston expansion with plans for new site

Dive Brief: Fresh off the dedication of a major new building in Boston’s Seaport, Vertex Pharmaceuticals said it’s making plans for yet another facility that …

Continue Reading →

Vertex gets positive trial results for non-opioid painkiller in boost to pipeline

Dive Brief: Vertex plans to advance an experimental drug it’s developing for acute pain into late-stage testing later this year after reporting positive results from …

Continue Reading →

Vertex plans path to FDA for top drug prospect

Dive Brief: Vertex will begin late-stage testing of one of its top drug prospects later this month, announcing on Tuesday plans for a Phase 2/3 …

Continue Reading →

Amgen partners with Arrakis to develop drugs aimed at RNA

Dive Brief: Amgen will team with Arrakis Therapeutics to develop oral drugs that target and destroy RNA, announcing a deal Tuesday that will pay the Waltham, …

Continue Reading →
Boehringer Ingelheim

Boehringer Ingelheim takes next step in development of cystic fibrosis gene therapy

Boston biotech Vertex is the leading developer of cystic fibrosis medicines. Its four approved drugs can treat most patients. Trikafta, the one most recently approved …

Continue Reading →

Vertex, looking to broaden its gene editing abilities, asks a young biotech for help

Vertex is best known for its work in cystic fibrosis, having developed four approved medicines that, by the company’s estimates, can treat about 90% of …

Continue Reading →

Vertex, CRISPR gene-editing therapy hit with clinical hold

U.S. regulators have placed a clinical hold on CRISPR Therapeutics’ lead candidate, spurring a double-digit drop in the Swiss biotech’s stock value by Thursday morning. …

Continue Reading →